Netherlands Cancer Institute

NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES

Retrieved on: 
Wednesday, March 27, 2024
WEE1, Netherlands Cancer Institute, Bernards, Cell, Professor, Malignancy, Neoplasm, Cancer, Death, Cancer Discovery (journal), Vaccine

PASADENA, CA, March 27, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, announced today publication of pre-clinical data in the online journal, Cancer Discovery, showing that its lead clinical compound, LB-100, can force cancer cells to give up their cancer-causing properties in a paper entitled “Paradoxical activation of oncogenic signaling as a cancer treatment strategy.” The finding opens a potentially new treatment strategy in addition to LIXTE’s current three clinical trials.

Key Points: 
  • The deliberate hyper-activation of cancer signals becomes lethal when combined with an inhibitor of the WEE1 kinase.
  • This well-tolerated combination proved to be highly effective in killing colon cancer cells in animal models of cancer and in cell culture.
  • Resistance to LB-100 therapy, however, has been shown to be associated with cancer cells becoming less malignant.
  • Although cancer-causing signals force cancer cells to become more cancerous, the hyper-activation of these signals by LB-100 forces cancer cells to suppress these signals and thus become less cancerous.

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Retrieved on: 
Thursday, March 21, 2024
Stroke, Netherlands Cancer Institute, Conference, Development, Immunotherapy, GSK, Patient, Lung, DSM-IV codes, National Cancer Institute, MD Anderson Cancer Center, University, Doctor of Philosophy, NIH, Senior, Sarcoma, Clinical trial, Annual report, Bangladesh Technical Education Board, Squamous-cell carcinoma, OCCC, Pharmaceutical industry

PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company’s progress with its proprietary compound, LB-100.

Key Points: 
  • -- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers --
    PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc .
  • (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company’s progress with its proprietary compound, LB-100.
  • The clinical trial was initiated by, and is being conducted at, the University of Texas MD Anderson Cancer Center.
  • Dr. Bernards is a member of the Board of Directors of LIXTE.

 Asher Bio Announces Publications in Cancer Discovery Highlighting the Differentiated Profile of AB248, its CD8+ T Cell Selective IL-2 Product Candidate

Retrieved on: 
Wednesday, April 3, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Toxicity, Netherlands Cancer Institute, VLS, Therapeutic index, Cell, Patient, ICB, Neoplasm, Immunology, Hypertelorism, Cancer, Infection, Publication, Immunity, IL-2, NKI, CD8, Immune system, Division, NK, Autoimmunity, PD-1, Vaccine

The papers were authored by Asher Bio scientists and collaborators at The Netherlands Cancer Institute (NKI), respectively, and published online in Cancer Discovery on April 2, 2024.

Key Points: 
  • The papers were authored by Asher Bio scientists and collaborators at The Netherlands Cancer Institute (NKI), respectively, and published online in Cancer Discovery on April 2, 2024.
  • “These co-published manuscripts are the culmination of several years of great collaboration between Asher Bio scientists and our academic co-founders, Dr.
  • Asher Bio systematically evaluated the properties needed for effective cis-targeting to CD8+ T cells and generated AB248, a CD8+ T cell selective IL-2.
  • To evaluate this hypothesis, Asher Bio’s collaborators at the NKI performed a comprehensive analysis of T cell reinvigoration following treatment with AB248.

Labcorp Launches Labcorp® Plasma Detect™ Extending Leadership into Molecular Residual Disease (MRD) Clinical Research

Retrieved on: 
Friday, April 5, 2024
ACT, Lung cancer, Netherlands Cancer Institute, Risk, Patient, DNA, Research, Bladder cancer, NKI, MRD, Liquid biopsy, Recurrence, Plasma, Neoplasm, Medical imaging

BURLINGTON, N.C., April 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp® Plasma Detect™, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) molecular residual disease (MRD) solution in early stage colon cancer to identify patients at increased risk of recurrence after surgery or adjuvant chemotherapy (ACT). This solution, which is designed for research use but also suitable for clinical applications, can be applied across solid tumors with a scalable and standardized approach to facilitate faster turnaround times while maintaining high analytical performance.

Key Points: 
  • The launch of the Labcorp Plasma Detect MRD solution further enhances Labcorp's leadership in precision oncology across the solid tumor oncology care continuum.
  • Labcorp Plasma Detect builds on the successful deployment of two existing liquid biopsy platforms – Labcorp® Plasma Focus™, a targeted approach, and Labcorp® Plasma Complete™, a comprehensive profiling solution, both with utility for clinical research and clinical applications.
  • "Labcorp Plasma Detect delivers a high-impact solution for clinical research and biopharmaceutical drug development to support retrospective and prospective clinical trials with the goal of improving patient outcomes in early stage disease."
  • Labcorp Plasma Detect is currently clinically validated for early-stage colon cancer, with ongoing efforts to expand into other indications, including lung cancer and bladder cancer.

Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research

Retrieved on: 
Tuesday, February 27, 2024
Head, Doctor of Philosophy, Aggression, Utrecht University, PP2A, Patient, Netherlands Cancer Institute, Pharmaceutical industry

PASADENA, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, today announced that René Bernards, PhD, professor of molecular carcinogenesis at Utrecht University in Amsterdam and head of molecular carcinogenesis at the Netherlands Cancer Institute, will present new pre-clinical data on LIXTE’s lead compound, LB-100, at the Joint Conference of European and American Associations for Cancer Research this week in Dublin, Ireland. Dr. Bernards is also a member of LIXTE’s Board of Directors.

Key Points: 
  • Dr. Bernards is also a member of LIXTE’s Board of Directors.
  • In his presentation, “Unexpected, but Highly Synergistic Combinations for Cancer Therapy,” Dr. Bernards will present data on how stress imposed onto colon cancer cells by LB-100 drives cancer cells to evolve to less cancerous behavior.
  • “The findings underscore the unique and what we believe to be exciting features and mechanism of action of LIXTE’s PP2A inhibitor, LB-100,” said Dr. James Miser, LIXTE’s Chief Medical Officer.
  • “While conventional cancer drugs aim to inhibit oncogenic signaling, which tends to drive cancer cells into more aggressive behavior, LB-100 does exactly the opposite, overloading oncogenic signaling, and thereby forcing cells to downregulate the signals that are characteristic for cancer cells.

Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies

Retrieved on: 
Thursday, January 25, 2024
Publishing, Communications, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, NTRA, Patient, MRD, Research, Neoplasm, MD, DNA, Partnership, Risk, Recurrence, Netherlands Cancer Institute, Safety, Doctor of Philosophy, Biomarker, PCR, Neoadjuvant therapy, Medical imaging

The study enrolled a total of 25 patients (20 pancreatic, 5 colorectal), 21 of whom were Signatera-positive after locoregional treatment.

Key Points: 
  • The study enrolled a total of 25 patients (20 pancreatic, 5 colorectal), 21 of whom were Signatera-positive after locoregional treatment.
  • Signatera dynamics were also used as a secondary endpoint to assess tumor biomarker response, together with serum tumor antigens.
  • The study reported that tumor biomarker responses were observed in 21/25 patients (84%), and ctDNA clearance was observed in 6/25 patients (24%).
  • “These studies also point to the valuable insights longitudinal ctDNA monitoring can provide in the evaluation of novel therapies.”

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

Retrieved on: 
Monday, November 13, 2023
Doxorubicin, Squamous-cell carcinoma, Research, Netherlands Cancer Institute, City, Progression-free survival, Sarcoma, BioRxiv, Clinical trial, Patient, Northwestern, MD Anderson Cancer Center, GEIS, Monroe Dunaway Anderson, GSK, PP2A, ASTS, Sarah Cannon Research Institute, SCRI, Cancer, University, Partnership, NKI, Immunotherapy, Pharmaceutical industry

(“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy benefit, today provided an update on its progress.

Key Points: 
  • (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy benefit, today provided an update on its progress.
  • GSK will provide dostarlimab and financial support for the clinical trial.
  • In addition to MD Anderson, the trial also will be open at Northwestern University’s Robert H. Lurie Comprehensive Cancer Center.
  • This trial will enroll up to 170 patients and will begin in partnership with GEIS clinical sites.

BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023

Retrieved on: 
Monday, October 23, 2023
Patient, NKI, Ovarian cancer, ESMO, American Society of Clinical Oncology, BioNTech, RNA, DCR, Neurotoxicity, Entrepreneurship, Society, CLDN6, Annual general meeting, Tumor antigen, ORR, Netherlands Cancer Institute, BNTX, Safety, ASCO, Vaccine, Pharmaceutical industry

The data show encouraging signs of clinical activity and an increased persistence of cancer-specific CAR-T cells when combined with CARVac.

Key Points: 
  • The data show encouraging signs of clinical activity and an increased persistence of cancer-specific CAR-T cells when combined with CARVac.
  • “Our goal is to unlock the potential of CAR-T for solid tumors and to help improve the outcomes for a broad range of hard-to-treat tumors,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech.
  • “BNT211 aims to address two of the key limitations of CAR-T cell approaches in solid tumors, namely the lack of suitable cancer-specific cell surface targets and the limited persistence of CAR-T cells.
  • Patients with germ cell tumors (n=16), ovarian cancer (n=17) and other solid tumor types (n=11) were treated.

Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Followed by Opdivo Demonstrates Significant Survival Benefits for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in Phase 3 CheckMate -901 Trial

Retrieved on: 
Tuesday, October 17, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Congress, HIV disease progression rates, Confidence interval, Bristol Myers Squibb, NYSE, Death, Abstract, Mesothelioma, Disclosure, Cancer, ORR, Risk, Safety, Lung cancer, Survival, European Society for Medical Oncology, ESMO, Doctor of Philosophy, Carcinoma, Immunotherapy, Checkmate, Clinical Genitourinary Cancer, EDT, PFS, Neoplasm, Progression-free survival, BMY, Netherlands Cancer Institute, Patient, CR, Pharmaceutical industry, Platinum, Nivolumab

At the 12- and 24-month landmark analyses, patients treated with upfront Opdivo plus chemotherapy experienced OS rates of 70.2% and 46.9%, respectively, compared to 62.7% and 40.7% with chemotherapy.

Key Points: 
  • At the 12- and 24-month landmark analyses, patients treated with upfront Opdivo plus chemotherapy experienced OS rates of 70.2% and 46.9%, respectively, compared to 62.7% and 40.7% with chemotherapy.
  • The landmark 12- and 24-month PFS rates were 34.2% and 23.5%, compared to 21.8% and 9.6% with chemotherapy.
  • The combination of Opdivo with cisplatin-based chemotherapy had a tolerable safety profile consistent with the known safety profiles of the individual components of the regimen.
  • “In patients with metastatic urothelial carcinoma, we often see poor durability of responses with chemotherapy alone in the first-line treatment setting.

LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration

Retrieved on: 
Monday, October 16, 2023
Cancer, NKI, Research, PP2A, Netherlands Cancer Institute, Drug combination, Immunotherapy, Patient, Pharmaceutical industry

PASADENA, CA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) announced that it has signed an agreement to expand its collaboration with the Netherlands Cancer Institute (NKI) and Oncode Institute to study drug synergies of LIXTE’s lead clinical compound, LB-100, with immunotherapy in various cancers. The new agreement also will seek to find synthetic lethal combinations in additional cancer types.

Key Points: 
  • PASADENA, CA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW) announced that it has signed an agreement to expand its collaboration with the Netherlands Cancer Institute (NKI) and Oncode Institute to study drug synergies of LIXTE’s lead clinical compound, LB-100, with immunotherapy in various cancers.
  • The new agreement also will seek to find synthetic lethal combinations in additional cancer types.
  • NKI, based in Amsterdam, Netherlands, is among the world’s leading comprehensive cancer centers.
  • Oncode Institute, headquartered in Utrecht, Netherlands, is a major independent cancer research center dedicated to translating research into practice and bringing discoveries into a clinic setting more quickly.